Checkpoint inhibitors target molecules responsible for the regulation of the immune response. The expression of programmed cell death protein 1 (PD-1) and its ligand, PD-L1, suppresses T cell activation. In response to a normal immune challenge, this pathway prevents hyperstimulation, and in malignancy this can halt immune responses against the tumor, enabling unimpeded progression.